RxDoctor Payments Data

Megan Leman

Family · Columbus, OHNPI 1235885906

Payments from drug & device makers

$476in general payments, 2019–2025

Across 12 payments — averaging $39.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$146
  • Otsuka America Pharmaceutical, Inc.$87
  • Xeris Pharmaceuticals, Inc.$72
  • Novo Nordisk$60
  • SK Life Science, Inc.$31
  • AbbVie$30
  • plus $52 from 3 others

What the payments were for

  • Food & beverage$476100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$476 in reported general payments places this provider in the 55th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$102,581
Medicare patients
224
Services billed
1,263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban79$32,554
OzempicSemaglutide29$29,718
TrulicityDulaglutide28$23,755
JanuviaSitagliptin Phosphate16$9,727
Breo ElliptaFluticasone/Vilanterol21$9,348
FarxigaDapagliflozin Propanediol16$8,625
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog54$8,536
ShingrixVaricella-Zoster Ge/As01b/Pf37$7,879
MyrbetriqMirabegron24$6,083
Fiasp FlextouchInsulin Aspart (Niacinamide)16$6,059
XareltoRivaroxaban14$5,300
OxycontinOxycodone Hcl19$5,013
Atorvastatin Calcium238$4,614
Lantus SolostarInsulin Glargine,hum.Rec.Anlog89$4,376
FiaspInsulin Aspart (Niacinamide)11$3,491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Fiasp$60$33,21040 claims
AstraZenecaFarxiga$17$8,62516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 6,812 family providers in Ohio.

Other family in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →